The medicines of tomorrow will keep being optimized for some people and not others.
Africa carries nearly a quarter of the world's disease burden, yet its people remain largely absent from the clinical trials that determine how medicines work and for whom. This absence is not incidental — it reflects deep structural inequities in research funding, infrastructure, and historical trust — and its consequences are measured in treatments that may not work as intended for the populations who need them most. The question of who gets included in the data is, ultimately, a question of whose lives are considered worth optimizing for.
- African populations bear a disproportionate share of global illness while contributing minimally to the clinical trial data that shapes how drugs are developed and approved worldwide.
- Genetic diversity, co-infections, nutritional conditions, and environmental realities unique to African contexts are routinely absent from trial design, meaning approved medicines may perform unpredictably across the continent.
- Decades of underfunded research infrastructure and a legacy of exploitative study practices have created both a practical and a trust deficit that pharmaceutical companies and funding bodies have been slow to address.
- Doctors and patients across Africa are left applying evidence built on other populations, absorbing unknown risks and delayed access while carrying the heaviest disease burden on earth.
- A growing recognition among funders and institutions is beginning to shift resources toward African research capacity, but commitments remain far smaller than the scale of the problem demands.
Africa bears nearly a quarter of the world's disease burden — malaria, tuberculosis, HIV, and a rising wave of noncommunicable diseases — yet its populations are largely absent from the clinical trials that determine which drugs work and how they should be used. The overwhelming majority of such trials are conducted in Europe, North America, and a handful of wealthy regions, with African participants included, when at all, as a marginal subset of studies designed and led elsewhere.
This absence has real consequences. People of African descent carry distinct genetic variations that affect how medications are metabolized, and environmental factors — co-infections, nutritional status, access to clean water — shape how diseases progress and how treatments perform. Medicines optimized through trials that excluded African populations may behave differently, or less effectively, in the very communities that need them most. Side effects or efficacy gaps may go undetected simply because no one was systematically watching.
The structural roots of this imbalance run deep. Clinical research demands infrastructure — equipped hospitals, trained staff, regulatory frameworks, and sustained funding — that many African nations have not received. Pharmaceutical companies gravitate toward regions where that groundwork already exists. A historical legacy of exploitative research practices has also made African communities understandably cautious about participation, even in well-intentioned studies.
Addressing the gap requires more than acknowledgment. It demands investment in African laboratories, training programs, and regulatory capacity. It requires that African populations be included in trial design from the outset, and that African scientists lead research on diseases affecting their own communities. Some funders and companies are beginning to act, but the resources committed remain far below what the problem demands. Until African participation becomes standard rather than exceptional, the medicines of the future will continue to be built for some of humanity — and not all of it.
Africa shoulders nearly a quarter of the world's disease burden. Yet when pharmaceutical companies and research institutions design the clinical trials that determine which drugs work and how they should be used, African patients are largely absent from the data. This gap—between the weight of illness borne by a continent and its minimal presence in the studies that shape global medicine—represents one of the most consequential blind spots in modern medical research.
The numbers tell a stark story. While African nations grapple with malaria, tuberculosis, HIV, and a rising tide of noncommunicable diseases, the vast majority of clinical trials that establish drug safety and efficacy are conducted in Europe, North America, and a handful of other wealthy regions. When researchers do recruit African participants, it is often as an afterthought, a small subset added to trials designed and led elsewhere. The result is a body of medical knowledge built on bodies that do not reflect the genetic diversity, disease patterns, or environmental realities of the African continent.
This matters in concrete ways. A drug deemed safe and effective in a trial conducted primarily on European or American populations may behave differently in people of African descent, who carry distinct genetic variations that affect how medications are metabolized. Environmental factors—the prevalence of co-infections, nutritional status, access to clean water—shape how diseases progress and how treatments perform. Yet these variables are rarely centered in trial design. The medicines that emerge from this process are optimized for populations that were well-represented in the research, not for those who were not.
The structural reasons for this imbalance run deep. Clinical trials require infrastructure: hospitals with specific equipment, trained research staff, regulatory frameworks, and funding. Many African nations lack the investment in research capacity that wealthier countries take for granted. Pharmaceutical companies, driven by profit and efficiency, naturally gravitate toward conducting trials where the groundwork already exists. There is also a historical dimension—a legacy of exploitative research practices that has made African communities justifiably wary of participating in studies, even well-intentioned ones.
The consequences ripple outward. When treatments are not tested on African populations, doctors and patients in those regions must rely on evidence generated elsewhere and hope it applies to them. They may lack access to drugs altogether, or access them only after years of delay. When side effects or efficacy issues emerge in African populations, they may go undetected because no one was systematically watching for them. The people bearing the heaviest disease burden are the least likely to benefit from advances in medical science.
Addressing this requires more than good intentions. It demands sustained investment in African research infrastructure—laboratories, training programs, regulatory capacity. It requires that trial design be reimagined to include African populations from the outset, not as an afterthought. It means funding research institutions across the continent so that African scientists can lead studies on diseases that affect their own communities. It means acknowledging that equitable medicine cannot be built on unequal data.
Some progress is underway. Funding bodies and pharmaceutical companies are beginning to recognize the problem and commit resources to change. But the scale of investment remains far below what is needed. Until African participation in clinical trials becomes the norm rather than the exception, the medicines of the future will continue to be optimized for some of humanity and not others.
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter so much where a clinical trial happens? Isn't a drug that works just a drug that works?
A drug's safety and effectiveness can depend on the people taking it. Genetics, environment, other diseases you might have—these all shape how a medicine behaves in your body. If a trial doesn't include people like you, the doctors prescribing it are working partly blind.
So you're saying African patients are getting medicines that weren't tested on African bodies?
Exactly. And it's not because African patients don't need medicine. It's because the research infrastructure—the labs, the funding, the trained researchers—is concentrated elsewhere. It's cheaper and easier to run a trial in a place where that infrastructure already exists.
But surely pharmaceutical companies want their drugs to work for everyone?
They want their drugs to work for the people they're selling to. If those people are primarily in wealthy countries, that's where the trials happen. Africa is both the place with the most disease and the place least represented in the research meant to treat it.
What would it take to change this?
Real money. Building research capacity in African institutions so trials can happen there, led by African scientists studying diseases that matter to African communities. It's not complicated, but it's expensive and it requires patience. Right now, it's cheaper to do things the way they've always been done.
And if nothing changes?
Then the medicines of tomorrow will keep being optimized for some people and not others. The burden of disease and the benefit of research will stay mismatched.